Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Oct;30(10):4163-73.
doi: 10.1007/s00464-016-4788-y. Epub 2016 Feb 19.

Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis

Affiliations
Meta-Analysis

Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis

Robert J S Coelen et al. Surg Endosc. 2016 Oct.

Abstract

Background: Despite extensive preoperative staging, still almost half of patients with potentially resectable perihilar cholangiocarcinoma (PHC) have locally advanced or metastasized disease upon exploratory laparotomy. The value of routine staging laparoscopy (SL) in these patients remains unclear with varying results reported in the literature. The aim of the present systematic review was to provide an overview of studies on SL in PHC and to define its current role in preoperative staging.

Methods: A systematic review and meta-analysis were performed in PubMed and EMBASE regarding studies providing data on the diagnostic accuracy of SL in PHC. Primary outcome measures were the overall yield and sensitivity to detect unresectable disease. Secondary outcomes were the yield and sensitivity for recent studies (after 2010) and large study cohorts (≥100 patients) and specific (metastatic) lesions. Methodological quality of studies was assessed with the Quality Assessment of Diagnostic Accuracy Studies tool.

Results: From 173 records, 12 studies including 832 patients met the inclusion criteria. The yield of SL in PHC varied from 6.4 to 45.0 % with a pooled yield of 24.4 % [95 % confidence interval (CI) 16.4-33.4]. Sensitivity to detect unresectable disease ranged from 31.6 to 75 % with a pooled sensitivity of 52.2 % (95 % CI 47.1-57.2). Sensitivity was highest for peritoneal metastases (80.7 %, 95 % CI 70.9-88.3). Subgroup analysis revealed that the yield and sensitivity tended to be lower for studies after 2010. Considerable heterogeneity was detected among the studies.

Conclusions: The results of the pooled analyses suggest that one in four patients with potentially resectable PHC benefits from SL. Given considerable heterogeneity, a trend to lower yield in more recent studies and further improvement of preoperative imaging over time, the routine use of SL seems discouraging. Studies that identify predictors of unresectability, that enable selection of patients who will benefit the most from this procedure, are needed.

Keywords: Diagnostic accuracy; Perihilar cholangiocarcinoma; Resectability; Staging laparoscopy; Yield.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards Disclosures No financial grants or other fundings have been received in support of this study. The authors, Robert J. S. Coelen, Anthony T. Ruys, Marc G. H. Besselink, Olivier R. C. Busch and Thomas M. van Gulik, declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Flowchart of study selection process
Fig. 2
Fig. 2
Risk of bias and applicability concerns for each included study
Fig. 3
Fig. 3
Risk of bias and applicability concerns presented as percentages across the included studies
Fig. 4
Fig. 4
Meta-analysis of yield of SL in PHC among included studies
Fig. 5
Fig. 5
Meta-analysis of sensitivity of SL to detect unresectable disease and specific lesions in PHC among included studies

Similar articles

Cited by

References

    1. Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg. 2014;399:693–705. doi: 10.1007/s00423-014-1210-x. - DOI - PubMed
    1. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281. doi: 10.1056/NEJMoa0908721. - DOI - PubMed
    1. Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg. 2009;250:210–218. doi: 10.1097/SLA.0b013e3181afe0ab. - DOI - PubMed
    1. Matsuo K, Rocha FG, Ito K, D’Angelica MI, Allen PJ, Fong Y, Dematteo RP, Gonen M, Endo I, Jarnagin WR. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012;215:343–355. doi: 10.1016/j.jamcollsurg.2012.05.025. - DOI - PubMed
    1. Ruys AT, van Haelst S, Busch OR, Rauws EA, Gouma DJ, van Gulik TM. Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World J Surg. 2012;36:2179–2186. doi: 10.1007/s00268-012-1638-5. - DOI - PMC - PubMed